“Adequate dose” in the drug treatment of mental disorders
https://doi.org/10.31363/2313-7053-2024-837
Abstract
The article discusses the use of different doses of psychotropic drugs in the treatment of mental disorders. It is known that the number of responders is about two thirds of all patients, which according to the “three sigma” rule for the normal distribution of cases, fits into the range of one sigma. The hypothetical calculation of the relative proportions of patients responding to treatment in low, mid-range and high doses is given. In accordance with this, the use of a mid-range treatment doses is justified, thereby the number of potential responders increases almost twice as compared with the use of small doses. Within the framework of pharmacodynamics, the probability of the development of dose-dependent effects is assessed, including both desirable and untoward effects of various pharmacological classes of psychotropic drugs in different doses.
About the Authors
V. L. Kozlovskii
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Vladimir L. Kozlovskii
St. Petersburg
N. V. Kozlovskaya
St. Petersburg State University
Russian Federation
Russian Federation
Nadezhda V. Kozlovskaya
St. Petersburg
D. N. Kosterin
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Dmitry N. Kosterin
St. Petersburg
O. V. Lepik
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Olga V. Lepik
St. Petersburg
M. Yu. Popov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Mikhail Yu. Popov
St. Petersburg
References
1. Балашов А.М. К вопросу о резистентности к фармакотерапии. Журнал неврологии и психиатрии им. C.C. Корсакова. 2009;109(1):90-91. Balashov AM. To the problem of pharmacological resistance. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;109(1):90-91. (In Russ.).
2. Бурчинский С.Г. Проблема фармакорезистентности при лечении антидепрессантами и возможности ее преодоления. Таврический журнал психиатрии. 2010;14(50):7-10. Burchinskii SG. The problem of pharmacoresistance in treatment with antidepressants and the possibility of overcoming it. Tavricheskii zhurnal psikhiatrii. 2010;14(50):7-10. (In Russ.).
3. Козловский В.Л. Нейроэволюционный подход в психофармакологии (к пониманию фармакодинамики психотропных препаратов). Психическое здоровье. 2016;14(10):56-60. Kozlovskii VL. Neuroevolutionary approach to psychopharmacology (towards the understanding of the pharmacodynamics of psychotropic drugs). Psikhicheskoe zdorov’e. 2016;14(10):56-60. (In Russ.).
4. Козловский В.Л. Рациональная фармакотерапия в психиатрии. Врач. 2012;12:21-26. Kozlovskii VL. Rational pharmacotherapy in psychiatry. Vrach. 2012;12:21-26. (In Russ.).
5. Козловский В.Л., Незнанов Н.Г. Эволюционные аспекты психопатологии и перспективы развития психофармакологии в свете представлений о модульной организации работы мозга. Журнал неврологии и психиатрии им. C.C. Корсакова. 2016;116(2):116-123. Kozlovskii VL, Neznanov NG. Evolutionary aspects of psychopathology and perspectives of psychopharmacology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. (In Russ.). https://doi.org/10.17116/jnevro201611621116-123
6. Козловский В.Л., Попов М.Ю. Биологические предпосылки формирования лекарственной резистентности в психиатрии и фармакодинамические подходы к ее преодолению. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(10):137-142. Kozlovskii VL, Popov MYu. Biological aspects of treatment resistance in psychiatry and pharmacodynamic approaches to its management. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(10):137-142. (In Russ.). https://doi.org/10.17116/jnevro2020120101137
7. Марута Н.А., Явдак И.А., Колядко С.П., Череднякова Е.С. Резистентные тревожно-фобические расстройства (факторы формирования и методы коррекции). Таврический журнал психиатрии. 2014;18(66):5-12. Maruta NA, Yavdak IA, Kolyadko SP, Cherednyakova ES. Resistant anxiety-phobic disorders (factors of development and methods of correction). Tavricheskii zhurnal psikhiatrii. 2014;18(66):5-12. (In Russ.).
8. Мюллер М., Регенбоген Б., Саш Ж., Эйк Ф., Харттер С., Хьёмке К. Гендерные аспекты в терапии стационарных пациентов с шизофренией амисульпиридом: терапевтическое исследование с регистрацией побочных эффектов лекарственных средств. Социальная и клиническая психиатрия. 2007;17(3):66-71. Muller MJ, Regenbogen B, Sache J, Eich F, Hartter S, Hiemke C. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: A therapeutic drug monitoring study. Social’naya i Klinicheskaya Psihiatriya. 2007;17(3):66-71. (In Russ.).
9. Николлс Дж.Г., Мартин А.Р., Валлас Б.Дж., Фукс П. От нейрона к мозгу. Пер с англ. М.: Едиториал УРСС, 2003. Nikolls Dzh.G., Martin A.R., Vallas B.Dzh., Fuks P. Ot neirona k mozgu. Per s angl. M.: Editorial URSS, 2003. (In Russ.).
10. Попов М.Ю., Козловская П.В. Является ли «эквивалентная хлорпромазиновая» доза в психофармакотерапии отражением хорошей клинической практики? Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2016;(2):15-20. Popov MYu, Kozlovskaya PV. Is the «equivalent chlorpromazine» dose in psychopharmacotherapy consistent with Good Clinical Practice? Obozrenie Psihiatrii i Medicinskoj Psihologii im. V.M. Bekhtereva. 2016;(2):15-20. (In Russ.).
11. Смирнов А.В., Дунин-Барковский И.В. Курс теории вероятностей и математической статистики для технических приложений. М.: Наука, 1969. Smirnov A.V., Dunin-Barkovskii I.V. Kurs teorii veroyatnostei i matematicheskoi statistiki dlya tekhnicheskikh prilozhenii. M.: Nauka, 1969. (In Russ.)
12. Энтони П.К. Секреты фармакологии. Пер. с англ. под ред. Д.А. Харкевича. М.: Медицинское информационное агентство, 2004. Entoni P.K. Sekrety farmakologii. Per. s angl. pod red. D.A. Kharkevicha. M.: Meditsinskoe informatsionnoe agentstvo, 2004. (In Russ.).
13. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessivecompulsive disorder. CNS Drugs. 2011;25(7):585-596. https://doi.org/10.2165/11587860-000000000-00000
14. Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78. https://doi.org/10.1177/0269881119889296
15. Boehm S, Kubista H. Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev. 2002;54(1):43-99. https://doi.org/10.1124/pr.54.1.43
16. Bonifaz-Peña V, Contreras AV, Struchiner CJ, Roela RA, Furuya-Mazzotti TK, Chammas R, et al. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. PLoS One. 2014;9(11):e112640. https://doi.org/10.1371/journal.pone.0112640
17. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res. 1974;11:65-69. https://doi.org/10.1016/0022-3956(74)90071-5
18. Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13-23. https://doi.org/10.1080/13651501.2016.1248852
19. Hamani C., Holtzheimer P., Lozano A.M., Mayberg H. (editors). Neuromodulation in Psychiatry, First Edition. John Wiley & Sons, Ltd., 2016.
20. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378. https://doi.org/10.3109/15622975.2012.696143
21. Iwamoto Y, Kawanishi C, Kishida I, Furuno T, Fujibayashi M, Ishii C, Ishii N, Moritani T, Taguri M, Hirayasu Y. Dose-dependent effect of antipsychotic drugs on autonomic nervous system activity in schizophrenia. BMC Psychiatry. 2012;12:199. https://doi.org/10.1186/1471-244X-12-199
22. Kapur S, Wadenberg ML, Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry. 2000;45(3):241-6. https://doi.org/10.1177/070674370004500302
23. Krauss G. Biochemistry of Signal Transduction and Regulation, 3rd, Completely Revised Edition. Weinheim: Wiley-VCH, 2003.
24. Leonard B.E. Fundamentals of psychopharmacology. John Wiley & Sons, Chichester, 1992.
25. Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia Am J Psychiatry. 2020;177(4):342-353. https://doi.org/10.1176/appi.ajp.2019.19010034
26. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, Geddes J, Davis JM. Dose equivalents for second-generation antipsychotic drugs: The classical mean dose method. Schizophr Bull. 2015;41(6):1397-1402. https://doi.org/10.1093/schbul/sbv037
27. MacQueen G, Santaguida P, Keshavarz H, Jaworska N, Levine M, Beyene J, Raina P. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11-23. https://doi.org/10.1177/0706743716664885
28. Nosè M, Tansella M, Thornicroft G, Schene A, Becker T, Veronese A, Leese M, Koeter M, Angermeyer M, Barbui C. Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol. 2008;23(5):287-290. https://doi.org/10.1097/YIC.0b013e328303ac75
29. Pineyro G, Blier P. Autoregulation of serotonin neurons: Role in antidepressant drug action. Pharmacol Rev. 1999;51(3):533-591.
30. Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem. 1988;34(5):822-828.
31. Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G, Zhou J, McLeod H, Adeyemo A, Rotimi CN. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J. 2014;14(3):217-222. https://doi.org/10.1038/tpj.2013.24
32. Sethi S, Sharma M, Malik A. Dose-dependent galactorrhea with quetiapine. Indian J Psychiatry. 2010;52(4):371-372. https://doi.org/10.4103/0019-5545.74315
33. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific basis and practical application. Cambridge University Press, 2013.
34. Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC. Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophr Res. 2011;133(1- 3):54-62. https://doi.org/10.1016/j.schres.2011.09.016
35. Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res. 2021;402:113098. https://doi.org/10.1016/j.bbr.2020.113098
Review
For citations:
Kozlovskii V.L., Kozlovskaya N.V., Kosterin D.N., Lepik O.V., Popov M.Yu. “Adequate dose” in the drug treatment of mental disorders. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2024;58(1):8-15. (In Russ.) https://doi.org/10.31363/2313-7053-2024-837
Views:
700
Email this article 